Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Bar

Showing results (511-520 of 540) with videos related to

Pageof 54
Sort By:
Biorxiv : the Preprint Server for Biology|December 25, 2025
Selective infection and loss of PRDM1+ LN Tfh cells in uncontrolled HIV infection precludes formation of Tfh reservoirs under ARTVincent H Wu, Jayme M L Nordin, M Betina Pampena, et al.
Plos Pathogens|May 21, 2010
High Multiplicity Infection by HIV-1 in Men Who Have Sex with MenHui Li, Katharine J Bar, Shuyi Wang, et al.
The Journal of Clinical Investigation|February 11, 2021
CCR5-edited CD4+ T cells augment HIV-specific immunity to enable post-rebound control of HIV replicationPablo Tebas, Julie K Jadlowsky, Pamela A Shaw, et al.
The Journal of Clinical Investigation|May 1, 2024
CCR5-edited CD4+ T cells augment HIV-specific immunity to enable post-rebound control of HIV replicationPablo Tebas, Julie K Jadlowsky, Pamela A Shaw, et al.
Plos Pathogens|June 14, 2012
Early low-titer neutralizing antibodies impede HIV-1 replication and select for virus escapeKatharine J Bar, Chun-yen Tsao, Shilpa S Iyer, et al.
The Journal of Clinical Investigation|June 15, 2023
Brain microglia serve as a persistent HIV reservoir despite durable antiretroviral therapyYuyang Tang, Antoine Chaillon, Sara Gianella, et al.
Journal of the International AIDS Society|June 4, 2025
Analytical treatment interruption among women with HIV in southern Africa who received VRC01 or placebo in the Antibody Mediated Prevention Study: ATI stakeholder engagement, implementation and early clinical dataShelly Karuna, Fatima Laher, Sufia Dadabhai, et al.
The Journal of Clinical Investigation|March 16, 2026
Smac mimetic combined with eCD4-Ig reverses latency without reducing SHIV reservoirs in rhesus macaquesLars Pache, John K Bui, Lindsay M Klouser, et al.
Nature Medicine|April 15, 2020
CTLA-4 and PD-1 dual blockade induces SIV reactivation without control of rebound after antiretroviral therapy interruptionJustin Harper, Shari Gordon, Chi Ngai Chan, et al.
JAMA Network Open|January 25, 2022
Association of Convalescent Plasma Treatment With Clinical Status in Patients Hospitalized With COVID-19: A Meta-analysisAndrea B Troxel, Eva Petkova, Keith Goldfeld, et al.
Pageof 54

Showing results (511-520 of 540) with videos related to

Sort By:
Pageof 54
Biorxiv : the Preprint Server for Biology|December 25, 2025
Selective infection and loss of PRDM1+ LN Tfh cells in uncontrolled HIV infection precludes formation of Tfh reservoirs under ARTVincent H Wu, Jayme M L Nordin, M Betina Pampena, et al.
Plos Pathogens|May 21, 2010
High Multiplicity Infection by HIV-1 in Men Who Have Sex with MenHui Li, Katharine J Bar, Shuyi Wang, et al.
The Journal of Clinical Investigation|February 11, 2021
CCR5-edited CD4+ T cells augment HIV-specific immunity to enable post-rebound control of HIV replicationPablo Tebas, Julie K Jadlowsky, Pamela A Shaw, et al.
The Journal of Clinical Investigation|May 1, 2024
CCR5-edited CD4+ T cells augment HIV-specific immunity to enable post-rebound control of HIV replicationPablo Tebas, Julie K Jadlowsky, Pamela A Shaw, et al.
Plos Pathogens|June 14, 2012
Early low-titer neutralizing antibodies impede HIV-1 replication and select for virus escapeKatharine J Bar, Chun-yen Tsao, Shilpa S Iyer, et al.
The Journal of Clinical Investigation|June 15, 2023
Brain microglia serve as a persistent HIV reservoir despite durable antiretroviral therapyYuyang Tang, Antoine Chaillon, Sara Gianella, et al.
Journal of the International AIDS Society|June 4, 2025
Analytical treatment interruption among women with HIV in southern Africa who received VRC01 or placebo in the Antibody Mediated Prevention Study: ATI stakeholder engagement, implementation and early clinical dataShelly Karuna, Fatima Laher, Sufia Dadabhai, et al.
The Journal of Clinical Investigation|March 16, 2026
Smac mimetic combined with eCD4-Ig reverses latency without reducing SHIV reservoirs in rhesus macaquesLars Pache, John K Bui, Lindsay M Klouser, et al.
Nature Medicine|April 15, 2020
CTLA-4 and PD-1 dual blockade induces SIV reactivation without control of rebound after antiretroviral therapy interruptionJustin Harper, Shari Gordon, Chi Ngai Chan, et al.
JAMA Network Open|January 25, 2022
Association of Convalescent Plasma Treatment With Clinical Status in Patients Hospitalized With COVID-19: A Meta-analysisAndrea B Troxel, Eva Petkova, Keith Goldfeld, et al.
Pageof 54